Association between response to gemcitabine-based neoadjuvant therapy and efficacy of gemcitabine plus nab-paclitaxel for recurrent pancreatic ductal adenocarcinoma
International Journal of Clinical Oncology · 2026-08 · 31 (8) · 1607-1618
DOI: 10.1007/s10147-026-03071-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 04.07.2026. Verfasst von Takumi Kinomoto und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan. Hauptthemen laut MEDLINE: Deoxycytidine, Carcinoma, Pancreatic Ductal, Neoplasm Recurrence, Local, Pancreatic Neoplasms. Die Arbeit nennt 49 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Gemcitabine-based neoadjuvant therapy is frequently employed to enable curative resection of pancreatic ductal adenocarcinoma. Gemcitabine plus nab-paclitaxel (GnP) is often given to patients who relapse post-resection, resulting in multiple courses of gemcitabine-containing treatment regimens. However, the effect of prior gemcitabine-based neoadjuvant therapy on the efficacy of GnP therapy remains unclear. This study aimed to determine whether prior gemcitabine-based neoadjuvant therapy affects the therapeutic outcomes of GnP in patients with recurrent pancreatic ductal adenocarcinoma following curative resection. METHODS: We retrospectively analyzed 51 patients with resectable and borderline resectable pancreatic ductal adenocarcinoma who received gemcitabine-based neoadjuvant chemoradiotherapy, underwent curative-intent surgery, and were treated with GnP post-recurrence. Patients were divided into high-regression (≥ 30% reduction in tumor diameter; 32 patients) and low-regression (< 30%; 19 patients) groups based on the tumor reduction rate during neoadjuvant therapy. RESULTS: Multivariate analysis identified tumor regression and the time from surgery to recurrence as independent prognostic factors for progression-free survival of GnP therapy following recurrence. Median progression-free survival was significantly longer in the high-regression group (11.8 vs. 5.8 months, p = 0.010). The objective response rate to GnP was significantly higher in the high-regression than low-regression groups (43.8% vs. 10.5%; p = 0.015). CONCLUSIONS: Patients with greater tumor regression during gemcitabine-based neoadjuvant therapy had better progression-free survival and treatment response to GnP therapy following recurrence. These findings suggest that treatment response to neoadjuvant therapy correlates with post-recurrence outcomes and contributes to the advancement of treatment strategies for recurrent pancreatic ductal adenocarcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan.
- Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan. ikezawa-ke@oici.jp.
- Department of Gastroenterology and Hepatology, Kansai Rosai Hospital, Amagasaki, Japan. ikezawa-ke@oici.jp.
- Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan.
- Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Japan.
Zitieren
APA
Kinomoto, T., Ikezawa, K., Gotoh, K., Kai, Y., Takada, R., Masumoto, T., Kawabata, M., Kishimoto, H., Ito, K., Urabe, M., Mukai, K., Nakabori, T., Shigekawa, M., Akita, H., Takahashi, H., Kobayashi, S., & Ohkawa, K. (2026). Association between response to gemcitabine-based neoadjuvant therapy and efficacy of gemcitabine plus nab-paclitaxel for recurrent pancreatic ductal adenocarcinoma. International Journal of Clinical Oncology, 31(8), 1607-1618. https://doi.org/10.1007/s10147-026-03071-6
Vancouver
Kinomoto T, Ikezawa K, Gotoh K, Kai Y, Takada R, Masumoto T, et al. Association between response to gemcitabine-based neoadjuvant therapy and efficacy of gemcitabine plus nab-paclitaxel for recurrent pancreatic ductal adenocarcinoma. International Journal of Clinical Oncology. 2026;31(8):1607-1618. doi:10.1007/s10147-026-03071-6
BibTeX
@article{Kinomoto2026,
author = {Kinomoto, Takumi and Ikezawa, Kenji and Gotoh, Kunihito and Kai, Yugo and Takada, Ryoji and Masumoto, Takanori and Kawabata, Masaki and Kishimoto, Hiroki and Ito, Kana and Urabe, Makiko and Mukai, Kaori and Nakabori, Tasuku and Shigekawa, Minoru and Akita, Hirofumi and Takahashi, Hidenori and Kobayashi, Shogo and Ohkawa, Kazuyoshi},
title = {Association between response to gemcitabine-based neoadjuvant therapy and efficacy of gemcitabine plus nab-paclitaxel for recurrent pancreatic ductal adenocarcinoma},
journal = {International Journal of Clinical Oncology},
year = {2026},
volume = {31},
number = {8},
pages = {1607--1618},
doi = {10.1007/s10147-026-03071-6}
}
EUVIMED